Emerging from Stealth Mode, Gene Editing Startup Prime Medicine Raises $315M
July 14, 2021
Source: CIPhotos/Getty Images
Prime Medicine, whose “search and replace” approach to gene editing underpins the second genome editing technology to be commercialized by the lab of David R. Liu, Ph.D., and colleagues, said today it has completed $315 million in financing, ending nearly a year of operation in stealth mode.
The financing consists of a $115 million Series A round and a $200 million series B round. Prime said proceeds from the financing will be used to continue building the company, rapidly advance towards clinical indications for its gene editing therapy candidates, and expand the capabilities of its platform.
Prime Time for Prime Medicine: Gene Editing Startup Raises $315M
genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
Prime Medicine Launches with $315 Million Financing to Deliver on the Promise of Prime Editing
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
First Positive Data of In Vivo CRISPR-Based Genome Editing in Humans Reported
June 28, 2021
A team of researchers based in the U.S., the U.K., and New Zealand from Intellia Therapeutics, Regeneron Pharmaceuticals, and clinical partners showed in a study that the companies’ lead
in vivo genome editing candidate NTLA-2001 generated a dose-dependent sustained reduction of protein linked to transthyretin (ATTR) amyloidosis following a single dose in six patients living with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).
The study is the first ever to support the safety and efficacy of
in vivo CRISPR genome editing in humans.
The New England Journal of Medicine and in a presentation that day at the 2021 Peripheral Nerve Society (PNS) Annual Meeting the researchers reported that a single 0.3 mg/kg dose of NTLA-2001 led to an 87% mean reduction in serum transthyretin (TTR) protein concentration in three of the ATTRv-PN patients by day 28, with individual re
New Era of Medicine : Researchers Publish First Positive Clinical Data for In Vivo Genome Editing in Humans
genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.